Vitamin K antagonists (VKAs) are the standard of care for patients with rheumatic heart disease related atrial fibrillation. Rivaroxaban is an anticoagulant used to treat and prevent blood clots. In this touchCARDIO interview, we speak with Professor Ganesan Karthikeyan (All India Institute of Medical Sciences, New Delhi, India) to discuss the risk factors of stroke in patients with rheumatic heart disease and the potential benefits of rivaroxaban over VKAs.Â
The abstract entitled ‘INVICTUS – Rivaroxaban versus VKA for rheumatic atrial fibrillation’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- What factors influence stroke risk in patients with rheumatic heart disease? (0:25)
- What are the potential advantages of rivaroxaban over vitamin K antagonists (VKAs) for prevention of stroke or systemic embolism in patients with rheumatic valvular heart disease? (2:04)
Disclosures: Ganesan Karthikeyan has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Atrial Fibrillation here and Cardiovascular Disease here
